Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma

Hong In Yoon  Jinsil Seong

Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea

Key Words
Hepatocellular carcinoma · Multimodal approach · Radiotherapy

Abstract
A multimodal approach to treatment is a basic oncologic principle with proven survival benefits for most cancer types. However, existing guidelines recommend single modalities for treating each stage of hepatocellular carcinoma (HCC). Nonetheless, multimodal approaches can be considered for HCC, depending on the characteristics of the disease in individual cases. Radiotherapy (RT), an effective local modality, is a critical element of most multimodal approaches. Improved RT technology and increased understanding of the tolerance of the liver to radiation have contributed to the popularity of RT for treating liver tumors in clinical practice. Consequently, numerous reports have described the effects of RT on liver cancer, despite a lack of stringent evidence for its benefits. RT can be delivered using various technologies and approaches, which may be the source of some confusion. For example, high-dose ablative RT can be curative on its own, or high-dose ablative or conventional RT can complement other treatments such as radiofrequency ablation and transarterial chemoembolization. Combinations of systemic agents and RT can also be applied. This review discusses the optimal selection of RT as part of a multimodal approach for HCC.
Introduction

Multimodal treatment is a basic oncologic principle that incorporates surgery, radiotherapy (RT), and chemotherapy [1, 2]. It has proven survival benefits for most cancer types [3–5]. However, a range of single modalities is generally recommended for treating each stage of hepatocellular carcinoma (HCC). Nevertheless, the multimodal approach may also be considered according to the disease characteristics in individual cases.

The Barcelona Clinic Liver Cancer (BCLC) staging system is most commonly used to stage HCC. It is endorsed by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Guidelines based on the BCLC staging system recommend a single modality as the standard treatment for each stage [6]. However, single-modality treatment frequently results in local or distant failure in the treatment of non-early-stage HCCs, which constitute the majority of cases [7].

The National Comprehensive Cancer Network (NCCN) guidelines recommend external-beam RT as a locoregional therapy for potentially resectable and unresectable HCC patients [8]. The Korean Liver Cancer Study Group (KLCSG) guidelines, established in 2003 [9] and updated in 2014 [10], recommend RT depending on the stage of HCC [10]. Both the 2003 and 2014 KLCSG guidelines support RT for the treatment of HCC because RT can exert an independent ablative effect and generally complements other treatments.

This article reviews the usage of RT in HCC treatment and discusses the clinical application of RT according to the 2014 KLCSG guidelines. Ongoing clinical trials and the optimal selection of RT as a part of multimodal approaches to HCC treatment are also discussed.

Beneficial Effects of RT against HCC

RT was previously not indicated for HCC because of the low tolerance of the liver to radiation. However, since Emami et al. estimated the tolerance dose for a 5% incidence of radiation-induced liver disease (RILD) in 5 years (TD5/5) after one-third liver irradiation to be 50 Gy at 1.8–2 Gy/fraction [11], several studies have confirmed high levels of tolerance of focal liver irradiation. For one-third of the liver irradiated, the estimated TD5/5 value is reportedly >40 Gy [12, 13]. A group from the University of Michigan also proposed that the delivery of >100 Gy may be possible without high risk of RILD if the effective irradiated liver volume is <25% [14]. Furthermore, technological progress in RT from three-dimensional conformal RT (3D-CRT) to intensity-modulated RT (IMRT), image-guided RT, and stereotactic body RT (SBRT) has enabled the delivery of high-precision RT for local HCC accompanied by minimal doses to the normal liver volume without inducing RILD [15–30].

RT for HCC can improve therapeutic outcomes through excellent local control, downstaging, conversion from unresectable to resectable status, and inhibition of intrahepatic metastasis. Excellent local control rates produced by SBRT can lead to favorable survival outcomes without severe radiation-induced toxicities, including 2-year overall survival (OS) rates of 53–61%, response rates of 45–63%, and grade 3 hepatic toxicity incidence rates of 6.5–16% [15, 16, 31, 32]. Local RT combined with systemic chemotherapy can result in downstaging and can subsequently convert the tumor status from unresectable to resectable. Downstaging may allow some patients to undergo radical resection, thereby improving long-term survival [33]. Local RT for major tumors and portal vein tumor thrombosis (PVTT) may prevent rapid intrahepatic metastasis, an adverse prognostic factor that makes it difficult to determine the best treatment strategy [18]. Compared to 3D-CRT, using intensity-modulated image-guided RT (IG-IMRT) as an advanced technique to apply high-dose RT to the partial liver in locally advanced HCC patients with good performance status and good
hepatic function reduces infield failure (29.2% vs. 44.3%, p=0.045) and improves survival (20 vs. 10 months, p<0.001) [18]. These findings suggest that high-dose, high-precision RT may have survival benefits.

**RT According to Modified UICC TNM Stage**

Unlike the BCLC staging system, the Union for International Cancer Control (UICC) staging system is anatomically based, describing the disease according to the extent of the primary tumor (T), regional lymph node involvement (N), and the presence (or otherwise) of distant metastases (M) [34, 35]. The UICC system describes the primary tumor site based on whether it meets the following criteria: (1) number of tumors: solitary; (2) diameter of the largest tumor: no more than 2 cm; and (3) no vascular or bile duct invasion. Stage T1 is defined as a primary tumor that fulfills all three criteria, T2 is a primary tumor that fulfills two of the three criteria, T3 is a primary tumor that fulfills one of the three criteria, and T4 is defined as a primary tumor that fulfills none of the criteria. Categories N and M describe regional lymph node involvement and distant metastasis, respectively. The modified UICC (mUICC) staging system categorizes HCC with T1, N0, and M0 as stage I and HCC with T2, N0, and M0 as stage II. T3N0M0 HCC patients are grouped as stage III. The mUICC staging system classifies T4N0M0 or N1M0 with any T stage as stage IVA and distant metastatic HCC as stage IVB. The fifth version of the mUICC staging system was adopted as the primary staging system for HCC by the KLCSG and National Cancer Centre (NCC) Korea in 2003.

The 2014 KLCSG guidelines recommend RT as an alternative for HCC patients unsuitable for surgical resection, radiofrequency ablation (RFA), ethanol injection, or transarterial chemoembolization (TACE) for mUICC stage I. For a single stage II HCC tumor >2 cm without vascular/ductal invasion, RT is also an alternative option in patients unsuitable for surgical resection, RFA, TACE, or liver transplantation. For a single tumor <2 cm with vascular invasion in stage II HCC, RT is one of the best therapeutic options. RT is also recommended as one of the best therapeutic options for a single stage III HCC >2 cm with major vascular invasion [10].

**SBRT for mUICC Stage I/II HCC**

Curative therapies can improve survival in early-stage HCC patients. However, the risk of complications from local ablation increases in tumors located below the hepatic dome and adjacent to the main portal vein (PV). RT may be a feasible alternative for these patients, especially for those who are inoperable or refuse surgery. Local high-dose RT, including SBRT, can be an appropriate alternative definitive or salvage treatment [36–41] (table 1). A French prospective trial evaluated the feasibility and efficacy of high-dose 3D-CRT in cirrhotic patients with small HCC: 66 Gy was delivered in 33 fractions, resulting in a tumor response rate of 92% [39]. Bae et al. also investigated the tumor response and local control rates in patients who underwent salvage hypofractionated RT of 50 Gy in 10 fractions. They reviewed 20 patients with HCC ≤5 cm and no PVTT; the complete response (CR) and in-field control rates were 35% and 85%, respectively [40]. Andolino et al. investigated the safety and efficacy of SBRT in 60 patients with primary, liver-confined HCC: the 2-year local control, progression-free survival (PFS) rate, and OS rate were 90%, 48%, and 67%, respectively [36]. Andolino et al. thereby demonstrated that SBRT is a safe, effective, and noninvasive option for HCC ≤6 cm and that SBRT can be considered as bridging locoregional therapy to transplantation or definitive therapy in patients ineligible for transplantation. O’Connor et al. reported the safety and efficacy of SBRT as a bridge to transplantation for HCC [42]; patients underwent orthotopic liver transplantation after SBRT with a median time from SBRT to liver transplantation of 113 days.
(range: 8–794 days). The 5-year overall and disease-free survival rates were both 100%, whereas the pathologic CR rate was 27%. These results show that SBRT has clinical value as a bridging therapy to transplantation as part of a multimodal approach.

Additional RT after Incomplete Response to TACE or RT for HCC Unfit for TACE in mUICC Stage II/III HCC

Patients diagnosed with stage II/III HCC can benefit from TACE [43]. However, TACE has limitations, including vascular shunting, recanalization around the tumor capsule, and the development of multiple feeding vessels [44, 45]. Although TACE is repeatedly performed to overcome these limitations, it commonly leads to outgrowth of HCCs refractory to TACE. RT can be useful as a complementary modality. TACE followed by RT is a feasible and effective complementary treatment for patients with incomplete necrosis after TACE [46–49] (table 2). A meta-analysis demonstrated that TACE in combination with RT significantly improves the 5-year survival (odds ratio [OR]: 4.47, 95% confidence interval [CI]: 2.08–9.61, p=0.0001) and tumor CR (OR: 2.58, 95% CI: 1.64–4.06, p=0.0001) rates compared to TACE alone [50]. A recent prospective phase II multicenter study investigated the efficacy and toxicity of RT following an incomplete response to TACE [51]; 31 patients who still had viable tumors after no more than three courses of TACE were enrolled, whereas patients with main PV invasion were excluded. The primary endpoint was tumor response. A best objective in-field response rate was achieved in 83.9% of patients, with 22.6% of patients achieving CR within 12 weeks of RT. The 2-year in-field PFS, PFS, and OS rates were 45.2%, 29.0%, and 61.3%, respectively. These findings demonstrate that early application of 3D-CRT can be a practical option in multimodal approaches for patients with incomplete necrosis after TACE. For patients unsuitable for TACE therapy because of low vascularity or PVTT, RT could be also effective and feasible. Yoon et al. reported the clinical outcomes of patients after TACE for primary tumors who underwent RT for HCC with PVTT [52]: 3.6% and 24.3% of such patients achieved CR and partial response (PR), respectively. The 1- and 2-year survival rates were 42.5% and 22.8%, respectively. The treatment response was an independent prognostic factor associated with OS (stable disease vs. CR and PR: hazard ratio [HR]: 3.06, 95% CI: 2.38–3.94; p<0.01) and treatment response was the most powerful predictor of survival in multivariate analysis (median survival of 19.4 months in responders and 7 months in non-responders, p<0.001) [52]. TACE plus RT resulted in significantly better OS than sorafenib only in advanced HCC (14.1 vs. 3.3 months before matching propensity scores and 8.9 vs. 3.1 months after matching propensity scores, p<0.001) [53]. A recent study demonstrated that SBRT is feasible and can be effective for HCC patients who are refractory to, or unsuitable for, TACE, showing a CR rate of 32.8%, a 2-year in-field failure-free rate of 66.8%, a median survival time (MST) of 20 months, and an RILD incidence rate of 9.4% [54].

Concurrent Chemoradiation with Hepatic Arterial Infusion in mUICC Stage II/III HCC with Vascular Invasion

PVTT, the most detrimental feature of vascular invasion in HCC, has been a major obstacle to HCC management and limits the therapeutic options. However, PVTT is sensitive to RT, and the response rate ranges from 25% to 61.5% [52, 55–58]. Furthermore, RT can boost the treatment responses of tumors and PVTT, and thus likely bestows a survival benefit [33, 52, 59–62]. In one retrospective study, preoperative RT induced PVTT necrosis in 8 patients (53.3%), and preoperative RT followed by surgery resulted in better outcomes than surgery alone for HCC with PVTT (5-year survival rate: 34.8% vs. 13.1%, p=0.0359) [61]. Better PVTT responses to RT were significantly associated with better survival [59, 60]. Several studies have indicated that hepatic arterial infusion concurrent chemoradiation (HAICCRT) may be a feasible and effective alternative for unresectable liver-confined HCC...
Table 1. Clinical outcomes of local high-dose RT in mUICC stage I HCC or stage II solitary HCC

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Authors</th>
<th>Ref. n</th>
<th>Previous treatments</th>
<th>Total/fractional dose (Gy)</th>
<th>Response rate (CR + PR, %)</th>
<th>MST (months)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-dose 3D-CRT</td>
<td>Mornex et al.</td>
<td>39 27</td>
<td>TACE, RFA, resection, PEI, systemic CTx in 15 patients</td>
<td>66/2</td>
<td>92 (CR 80, PR 12)</td>
<td>N/A</td>
<td>Prospective phase 2, small HCC (1 nodule ≤5 cm, or 2 nodules ≤3 cm)</td>
</tr>
<tr>
<td>SBRT</td>
<td>Tse et al.</td>
<td>38 41</td>
<td>RFA, TACE, CTx, resection, etc. in 19 patients</td>
<td>24–54/4–9</td>
<td>49 (CR 5, PR 44)</td>
<td>11.7 in 31 HCC patients</td>
<td>31 HCC and 10 IHC patients</td>
</tr>
<tr>
<td>SBRT</td>
<td>Andolino et al.</td>
<td>36 60</td>
<td>None</td>
<td>Median 44/14 for C-P A</td>
<td>70 (CR 30, PR 40)</td>
<td>2-yr. OS rate 67% Primary HCC &lt;6 cm</td>
<td></td>
</tr>
<tr>
<td>Hypofractionated RT</td>
<td>Bae et al.</td>
<td>40 20</td>
<td>TACE or RFA in all patients</td>
<td>50/5</td>
<td>CR 35</td>
<td>2-yr. OS rate 87.9% HCC ≤5 cm and no PVTT, Salvage RT to recurrent HCC</td>
<td></td>
</tr>
<tr>
<td>SBRT vs. non-SBRT</td>
<td>Huang et al.</td>
<td>41 36</td>
<td>Curative therapy in all patients</td>
<td>25–48/5–12</td>
<td>58.6 (CR 22, PR 36.6)</td>
<td>2-yr. OS rate 87.9% Matched pair analysis Recurrent HCC</td>
<td></td>
</tr>
<tr>
<td>SBRT as bridge therapy to LT</td>
<td>O’Connor et al.</td>
<td>42 10</td>
<td>TACE in 4 patients</td>
<td>33–54/11–18</td>
<td>Pathologic CR 27</td>
<td>5-yr. OS rate 100% All patients underwent SBRT followed by LT</td>
<td></td>
</tr>
</tbody>
</table>

PEI=percutaneous ethanol injection; CTx=chemotherapy; LT=liver transplantation; IHC=intrahepatic cholangiocellular carcinoma.

Table 2. Clinical outcomes of TACE plus RT in mUICC stage II/III HCC

<table>
<thead>
<tr>
<th>Treatments</th>
<th>Authors</th>
<th>Ref. n</th>
<th>Previous treatments</th>
<th>Total/fractional dose (Gy)</th>
<th>Response rate (CR + PR, %)</th>
<th>MST (months)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT + (TACE or surgery)</td>
<td>Zeng et al.</td>
<td>47 44</td>
<td>None</td>
<td>36–60/2</td>
<td>45.5</td>
<td>RT 8, non-RT 4</td>
<td>PVTT in 45 patients</td>
</tr>
<tr>
<td>3D-CRT + TACE</td>
<td>Yu et al.</td>
<td>49 81</td>
<td>TACE or no</td>
<td>35–50/3.5–5</td>
<td>CR 8.6, PR 61.7</td>
<td>14.7</td>
<td>Prospective phase 2, mUICC stage II-Iva, VI in 9</td>
</tr>
<tr>
<td>3D-CRT + TACE</td>
<td>Choi et al.</td>
<td>51 31</td>
<td>None</td>
<td>46–59.4/1.8–2</td>
<td>83.9 in-field, 64.5 for all tumors</td>
<td>2-yr. OS 61.3</td>
<td></td>
</tr>
<tr>
<td>3D-CRT + (TACE or TACI)</td>
<td>Yoon et al.</td>
<td>52 412</td>
<td>None</td>
<td>21–60/2–5</td>
<td>27.9</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>TACE + RT vs. sorafenib</td>
<td>Cho et al.</td>
<td>53 116</td>
<td>None</td>
<td>30–45/2–4.5</td>
<td>14.1 vs. 3.3</td>
<td>BCLC stage C</td>
<td></td>
</tr>
</tbody>
</table>

TACI=transcatheter arterial chemoinfusion; VI=vascular invasion.
with vascular invasion [33, 55, 62–64] (table 3). The MST of patients who undergo HAICCRT ranges from 11.4 to 13.1 months. The PVTT response to HAICCRT indicates significant survival improvement [62], with CR and PR rates of 14% and 48%, respectively. Moreover, PVTT CR is a significant prognostic factor (HR: 0.445, 95% CI: 0.205–0.968, p=0.041). The objective responses of both the primary tumor and PVTT are significantly associated with improved survival (median: 16.7 months, p=0.002). RT-induced downstaging can allow curative resection to be carried out and provide a curative opportunity for some unresectable liver-confined HCC patients [33]. Among 243 patients treated between 2005 and 2011, 41 (16.9%) underwent curative resection following HAICCRT. The response rate (CR + PR) was 65.9%, and the downstaging rate was 78%. Patients who underwent curative resection after HAICCRT exhibited significantly higher OS than those who did not (5-year OS: 49.6% vs. 9.8%; p<0.001). A nationwide cohort study also supports the use of HAICCRT as part of a multimodal approach [64]. After propensity score matching, the HAICCRT group had a significantly better OS (median: 11.4 months) than the non-HAICCRT group (median: 6.6 months, p=0.02); multivariate analysis of all patients showed HAICCRT was an independent prognostic factor for OS (non-HAICCRT vs. HAICCRT, HR: 1.48, 95% CI: 1.11–1.97, p=0.007).

**Multimodal Approaches Involving RT for Large, Unresectable HCC (≥5 cm)**

Multimodal approaches involving RT can affect outcomes in patients with large, unresectable HCCs. Shim et al. compared TACE followed by RT versus TACE alone or repeated TACE [48] (table 3). The inclusion criteria were as follows: (1) single tumors ≥5 cm in diameter receiving TACE as the primary treatment, and (2) patients with PV invasion exceeding the segmental branch. The response to TACE alone was incomplete in 69.5% of 105 patients. Of the 73 patients with HCC with an incomplete response to TACE, 38 underwent RT and 35 underwent repeated TACE alone. Comparison of RT following incomplete TACE with TACE alone showed that the addition of RT remedied incomplete necrosis after TACE and significantly increased 2-year OS (TACE alone vs. TACE plus RT, 14% vs. 37%, p=0.001). The improvement in survival was greater in patients with large tumors. Two-year survival rates for TACE plus RT versus TACE alone were 63% and 42%, respectively, for tumors 5–7 cm in diameter, 50% and 0% for tumors 8–10 cm in diameter, and 17% and 0% for tumors >10 cm in diameter. HAICCRT followed by hepatic arterial infusion chemotherapy (HAIC) or TACE and RT combination therapy also induced excellent intrahepatic control and improved survival in unresectable very large HCCs (≥10 cm) [65] (table 3). The MSTs of patients with very large HCCs who underwent RT and TACE combination therapy (15.3 months) and HAICCRT (12.8 months) were significantly higher than those of patients undergoing TACE alone (7.5 months) or HAIC alone (8.2 months); the time to intrahepatic progression was also significantly greater in those undergoing HAICCRT or combined RT and TACE compared with the other two groups. Multivariate analysis showed that multimodal approaches, including HAICCRT followed by HAIC and TACE and RT combination therapy, are significant independent prognostic factors that positively affect OS.

**Multimodal Approaches Involving RT for Multiple mUICC Stage II/III HCCs**

The role of local RT is more uncertain for multiple intrahepatic HCCs. In a study of 107 patients with multiple intrahepatic HCCs, local RT to the main tumor was beneficial if HCCs external to the RT field were already well controlled by another therapy. Patients with viable intrahepatic tumors external to the RT field showed poorer survival than those without such tumors, suggesting that RT is not effective in these patients [66] (table 3). The combination of HAICCRT to the main tumor with PVTT and TACE to other intrahepatic tumors is effective for advanced HCC with both PVTT and intrahepatic metastasis [67]. Median PFS and OS were 4.5 and 9.8 months, respectively. These findings suggest that local RT administered to the
<table>
<thead>
<tr>
<th>Treatments</th>
<th>Authors</th>
<th>Ref n</th>
<th>Previous treatments</th>
<th>Total/fractional dose (Gy)</th>
<th>Response rate (CR + PR, %)</th>
<th>MST (months)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAICCRT for HCC with VI</td>
<td>Han et al.</td>
<td>55 40</td>
<td>None</td>
<td>45 /1.8</td>
<td>45</td>
<td>13.1</td>
<td>All HCC with PVTT</td>
</tr>
<tr>
<td>HAICCRT</td>
<td>Choi et al.</td>
<td>62 100</td>
<td>TACE, no (70)</td>
<td>45–60 /1.8–3</td>
<td>62</td>
<td>11.6 (R 16.7/ Non-R 8.4)</td>
<td>mUICC T2-4 N0M0 with PVTT</td>
</tr>
<tr>
<td>HAICCRT ± RS</td>
<td>Lee et al.</td>
<td>33 243 (+RS 41)</td>
<td>None</td>
<td>45/1.8</td>
<td>65.9 (radiologic)/78 (DS) in +RS</td>
<td>23 in +RS</td>
<td>FRLV increased from 47.5% to 69.9% after HAICCRT</td>
</tr>
<tr>
<td>HAICCRT vs. non-HAICCRT</td>
<td>Yoon et al.</td>
<td>64 106/106</td>
<td>None</td>
<td>42.4–59.4 /1.8–2.5</td>
<td>N/A</td>
<td>HAICCRT 11.4/ non- 6.6</td>
<td>mUICC III-IVa Propensity score matching analysis</td>
</tr>
<tr>
<td>Multimodal approach for huge HCC</td>
<td>Shim et al.</td>
<td>48 38/35</td>
<td>None</td>
<td>36–59.4 /1.8</td>
<td>65.8% in TACE+RT</td>
<td>2-yr. OS 36.8%/14.3%</td>
<td>Tumor ≥5 cm</td>
</tr>
<tr>
<td>RT + TACE/HAICCRT</td>
<td>Kim et al.</td>
<td>65 35/149</td>
<td>None</td>
<td>36–60 /1.8–3</td>
<td>N/A</td>
<td>15.3/12.8</td>
<td>Tumor ≥10 cm</td>
</tr>
<tr>
<td>Multimodal approach for multiple HCC</td>
<td>Koom et al.</td>
<td>66 107</td>
<td>HAIC (49), ablation (3), none (55)</td>
<td>36–59.4 /1.8–2</td>
<td>62 in Group 1, 72 in 2, 74 in 3</td>
<td>35 in Group 1, 13 in 2, 19 in 3</td>
<td>Group 1: single tumor 2: all multiple tumors in RT field 3: in-field tumor with all controlled out-field tumors</td>
</tr>
<tr>
<td>HAICCRT (main) + TACE (intrahepatic metastasis)</td>
<td>Park et al.</td>
<td>67 30</td>
<td>None</td>
<td>45/1.8</td>
<td>32.1</td>
<td>9.8</td>
<td></td>
</tr>
</tbody>
</table>

R=responder; DS=downstaging; RS=radical resection; FRLV=functional residual liver volume.
main tumor in a multimodal approach can provide survival benefits for patients with multiple HCCs who have well-controlled intrahepatic tumors external to the RT field. However, a well-designed prospective trial is required for confirmation.

**Clinical Trials Investigating the Role of RT in Multimodal Approaches to HCC Treatment**

Clinical trials have investigated the effect and feasibility of RT for HCC. Five phase 3 clinical trials have been registered at ClinicalTrials.gov and are recruiting patients to evaluate the effect of RT in multimodal approaches to HCC treatment (table 4). Trial NCT02125396, titled Adjuvant Radiotherapy Comparing TACE for Curative HCC: a Randomized Controlled Trial, is investigating the efficacy of adjuvant RT compared to adjuvant TACE for HCC patients who have undergone curative surgery and have risk factors for recurrence on pathologic reports. Risk factors for recurrence are tumors >5 cm, multiple nodules, vascular invasion, the absence of tumor capsule, poorly differentiated tumor, and a narrow resection margin. The primary and secondary endpoints are OS and recurrence rate, respectively. Meanwhile, a randomized phase III trial titled A Trial on SBRT after Incomplete Transcatheter Arterial Embolization (TAE) or TACE versus Exclusive TAE or TACE for Inoperable HCC (NCT02323360) is recruiting participants to compare the effects of SBRT or a new cycle of TACE after incomplete TACE for unresectable HCC. Patients must have a single nodule ≤5 cm or one to three nodules ≤3 cm in diameter after incomplete TACE. The primary endpoint is local control. Two other clinical trials are currently recruiting participants to evaluate the effect of combining RT with sorafenib versus sorafenib alone for advanced HCC. The Randomized Controlled Trial of Proton Beam Radiotherapy+Sorafenib versus Sorafenib for Patients with Hepatocellular Carcinoma Exceeding San Francisco Criteria (NCT01141478) aims to determine whether proton beam RT plus sorafenib will produce better results than sorafenib alone for treating HCC patients with a tumor burden that exceeds the San Francisco criteria. The other trial, The Radiation Therapy Oncology Group 1112 trial titled Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (NCT01730937), is currently recruiting participants to compare the effect of SBRT followed by sorafenib with sorafenib alone for primary or recurrent advanced HCC. The primary endpoint of these two clinical trials is OS.

**Optimal RT in Multimodal Approaches to HCC Treatment**

**Hepatic Functional Reserve**

HCC patients are required to have sufficient hepatic functional reserve before RT. According to the 2014 KLCSG-NCC Korea practice guidelines [10], Child–Pugh class A or B patients are eligible for SBRT and fractionated RT [68]. Yoon et al. investigated whether poor hepatic function can predict radiation-induced hepatotoxicity according to the pre-RT value of the indocyanine green retention rate 15 min after administration (ICG-R15) in patients with HCC treated with RT [69]. The incidences of RILD in patients with ICG-R15 levels ≥22% and <22% before RT were 40.7% and 3.4%, respectively (p<0.001). Consequently, patients with poor hepatic functional reserve may be vulnerable to radiation-induced hepatic toxicity despite receiving an appropriate RT dose.

HCC patients hoping to undergo RT must meet several conditions to sustain sufficient hepatic functional reserve; these conditions take into account the tumor volume, the irra-
diated liver volume, and dose–volume parameters. According to the 2014 KLCSG-NCC Korea practice guidelines, the tumor volume must be limited to $\leq 70\%$ of the total liver volume [14, 70]. The liver volume receiving $\geq 30$ Gy must be constrained to $\leq 60\%$ of the total liver volume on dose–volume histograms for 3D-RT planning [71]. For SBRT, the normal liver volume receiving a total dose of $<15$ Gy must be $\geq 700$ ml or the mean normal liver dose (liver minus gross tumor volume) must be limited to $<28$ Gy in 2-Gy fractions [72, 73]. Several institutions have similarly applied dose–volume histogram parameter-based RT guidelines [74, 75].

**Published Dose Fractionation for Each RT Technique**

The dose prescribed for SBRT has been reported as total doses of $30–60$ Gy/$5–20$ Gy per fraction in several studies [15, 16, 31, 36, 40–42, 76]. With 3D-CRT or IMRT, total doses of $21–60$ Gy/$1.8–5$ Gy per fraction have been reported [18, 47, 49, 51, 59, 64, 65, 67, 77].

**Optimal RT Strategy according to Tumor Staging**

Until 2014, the NCCN guidelines recommended RT with evidence level 2B for unresectable HCC patients who were not transplant candidates only [8]. The 2015 NCCN version 2.0 guidelines consider locoregional therapies such as ablation, arterially directed therapy, and RT as preferred therapies for patients with unresectable disease and medically inoperable patients [8]. Furthermore, RT is suggested as a preferred treatment for potentially resectable HCC patients who are not amenable to resection or liver transplantation; the evidence level is 2B.

On the basis of several studies and guidelines, our recommendations for RT for the treatment of HCC are as follows (fig. 1). (1) For single small mUICC stage I/II HCCs without vascular invasion, high-dose RT such as SBRT is an alternative option in patients unsuitable for surgical resection, liver transplantation, RFA, ethanol injection, or TACE. (2) For mUICC stage II/III patients who exhibit an incomplete response to TACE, combination TACE and RT as salvage

---

**Table 4. Clinical trials investigating the role of RT in multimodal approaches to HCC treatment**

<table>
<thead>
<tr>
<th>Title</th>
<th>NCT number</th>
<th>Estimated enrollment</th>
<th>Arms</th>
<th>Primary endpoint</th>
<th>Secondary endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant Radiotherapy Comparing TACE for Curative HCC (ARTC-HCC)</td>
<td>NCT02125396</td>
<td>150</td>
<td>Arm 1: adjuvant RT Arm 2: TACE</td>
<td>OS</td>
<td>Recurrence rate</td>
</tr>
<tr>
<td>A Trial on SBRT after Incomplete TAE or TACE versus Exclusive TAE or TACE for Treatment of Inoperable HCC</td>
<td>NCT02323360</td>
<td>80</td>
<td>After TAE or TACE Arm 1: SBRT, Arm 2: TACE</td>
<td>Local control</td>
<td>OS, PFS, toxicity</td>
</tr>
<tr>
<td>Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients with Hepatocellular Carcinoma Exceeding San Francisco Criteria</td>
<td>NCT01141478</td>
<td>220</td>
<td>Arm 1: sorafenib Arm 2: proton beam RT plus sorafenib</td>
<td>OS</td>
<td>Radiological progression</td>
</tr>
<tr>
<td>Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer</td>
<td>NCT01730937</td>
<td>368</td>
<td>Arm 1: sorafenib Arm 2: SBRT plus sorafenib</td>
<td>OS</td>
<td>TTP, PFS, G4 or 5 adverse events, health-related quality of life</td>
</tr>
</tbody>
</table>

TTP=time to progression.
or adjuvant treatment can be considered. (3) For mUICC stage II/III/IVa HCC with vascular invasion or a large diameter, RT can be part of multimodal treatments such as HAICCRT and TACE plus RT; if satellite nodules can be included in the RT field of the major tumor, HAICCRT can be applied for multiple HCCs with vascular invasion. SBRT may also be considered for HCC with vascular invasion. (4) For multiple HCCs in mUICC stage III/IVa patients, a combination of RT for the main tumor and TACE for intrahepatic metastasis can be considered as an alternative treatment.

**Summary and Future Directions**

Thanks to recent advances in RT techniques and several studies supporting its clinical applicability, RT has become a feasible therapeutic option for HCC. Multimodal approaches involving RT can be considered for HCC ranging from very early to advanced stages. High-dose ablative RT delivered in a few fractions can be independently curative. A high ablative dose or conventional RT can complement incomplete results of other treatments such as RFA and TACE. Moreover, a combination of systemic agents and RT can be applied. However, additional randomized controlled trials are required to corroborate the role of multimodal approaches involving RT for the treatment of HCC.

**Disclosure Statement**

All authors state that there are no conflicts of interest.

**References**


